Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

The Star 6.6 DEAL: 35% OFF Digital Access

Monthly Plan

RM 13.90/month

RM 9.04/month

Billed as RM 9.04 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

AIM to explore business development with Beijing ZhenHealth Tech
Forest City SFZ can exceed RM2bil investment target this year
Weststar Maxus, Yinson Greentech ink deal for 300 electric commercial vans
Wawasan QI's Kami Builders issues RM90mil SRI sukuk
Heavyweight stocks lift Bursa Malaysia, pare losses at midday
Datuk Halipah Esa retires from SD Guthrie's sustainability and board tender committees
B15 biodiesel rollout could east inflation, reduce fiscal burden - CGS International
i-City partners TwinMatrix on developing AI-enhanced experiential AI living
Tanco hits limit down for third straight day, prompts further IDSS suspension
Japan's Nikkei recoups early losses as US signals end of Iran strikes

Others Also Read